Anaritide (Auriculin-Registered Trademark) is a 25-amino-acid synthetic form of atrial natriuretic peptide. Scios Nova was developing anaritide acetate for use in the treatment, prevention and diagnosis of acute renal failure, heart failure and hypertension. Scios suspended development of AURICULIN® anaritide based upon the results of an interim analysis of data from a 250-patient Phase III study in oliguric acute renal failure. The study was suspended due to the low probability that a positive outcome could be obtained with respect to its primary clinical endpoint, dialysis-free survival.

Tosactide is a synthetic peptide, a structural corticotropin analog (the first 28 amino acids of human adrenocorticotropin). The time course shows that the duration of action is short with a maximum effect at about 30 minutes and returns to a resting value soon after three hours. Tosactide has been used clinically.